Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a **combination topical or ophthalmic medication** containing four active ingredients: neomycin, polymyxin B, bacitracin, and hydrocortisone. - **Neomycin, polymyxin B, and bacitracin** are antibiotics that act synergistically to inhibit bacterial growth by interfering with protein synthesis (neomycin), disrupting bacterial cell membrane integrity (polymyxin B), and inhibiting cell wall synthesis (bacitracin). - **Hydrocortisone** is a corticosteroid that reduces inflammation, redness, swelling, and itching by activating anti-inflammatory pathways. This combination is mainly indicated for treating or preventing **bacterial skin and eye infections** and also for controlling associated inflammation. It is supplied as ointment for ophthalmic use and for topical skin application[1][3][5][7][14].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on neomycin + polymyxin B + bacitracin + hydrocortisone.